Cochrane · systematic review · CD013506
Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease
Ni, H, Aye, SZ, Naing, C · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
22
current version
GRADE rated
16
No studies
5
Included studies
NR
No studies 5 · 22.7%Ungraded 1 · 4.5%Very low 12 · 54.5%Low 4 · 18.2%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Intravenous magnesium sulfate + standard care compared to placebo + standard care for acute exacerbations of chronic obstructive pulmonary disease
Population: acute exacerbations of chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of people with hospital admissions (from the emergency room) Intravenous magnesium sulfate + standard care vs placebo + standard care | OR 0.45 [0.23, 0.88] | 3 studies · 170 participants | Low Downgraded: risk of bias, imprecision |
Proportion of people requiring non‐invasive ventilation Intravenous magnesium sulfate + standard care vs placebo + standard care | OR 0.74 [0.31, 1.75] | 2 studies · 107 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of people with serious adverse events Intravenous magnesium sulfate + standard care vs placebo + standard care | no estimate extracted | 1 study · 77 participants | Ungraded |
Length of hospital stay Intravenous magnesium sulfate + standard care vs placebo + standard care | no estimate extracted | 2 studies · 54 participants | Low Downgraded: risk of bias, imprecision |
Change in oxygen saturation (SpO2) Intravenous magnesium sulfate + standard care vs placebo + standard care | no estimate extracted | 1 study · 77 participants | Very low Downgraded: risk of bias, imprecision |
Change in dyspnoea score Intravenous magnesium sulfate + standard care vs placebo + standard care | no estimate extracted | 2 studies · 101 participants | Low Downgraded: risk of bias, imprecision |
Lung function: FEV1 change from baseline at 60 min Intravenous magnesium sulfate + standard care vs placebo + standard care | no estimate extracted | 1 study · 30 participants | Low Downgraded: imprecision |
Nebulised magnesium sulfate + standard care compared to placebo + standard care for acute exacerbations of chronic obstructive pulmonary disease
Population: acute exacerbations of chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of people with hospital admissions (from the emergency room) Nebulised magnesium sulfate + standard care vs placebo + standard care | OR 0.77 [0.21, 2.82] | 1 study · 109 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of people requiring ICU admission Nebulised magnesium sulfate + standard care vs placebo + standard care | OR 0.39 [0.15, 1] | 2 studies · 281 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of people requiring ventilatory support (NIV or assisted ventilation) Nebulised magnesium sulfate + standard care vs placebo + standard care | OR 0.33 [0.01, 8.2] | 1 study · 172 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of people with serious adverse events Nebulised magnesium sulfate + standard care vs placebo + standard care | no estimate extracted | NR | No studies |
Length of hospital stay Nebulised magnesium sulfate + standard care vs placebo + standard care | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Change in oxygen saturation (SaO2) Nebulised magnesium sulfate + standard care vs placebo + standard care | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Change in dyspnoea score Nebulised magnesium sulfate + standard care vs placebo + standard care | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Lung function: FEV1 at 60 min Nebulised magnesium sulfate + standard care vs placebo + standard care | no estimate extracted | 1 study · 109 participants | Very low Downgraded: risk of bias, imprecision |
Magnesium sulfate compared to standard care (ipratropium bromide) for acute exacerbations of chronic obstructive pulmonary disease
Population: acute exacerbations of chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of people with hospital admissions (from the emergency room) Magnesium sulfate vs standard care (ipratropium bromide) | OR 1.62 [0.78, 3.37] | 1 study · 124 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of people requiring endotracheal intubation Magnesium sulfate vs standard care (ipratropium bromide) | OR 1.69 [0.61, 4.71] | 1 study · 124 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of people with serious adverse events Magnesium sulfate vs standard care (ipratropium bromide) | no estimate extracted | NR | No studies |
Length of hospital stay Magnesium sulfate vs standard care (ipratropium bromide) | no estimate extracted | 1 study · 124 participants | Very low Downgraded: risk of bias, imprecision |
Change in oxygen saturation (SaO2) Magnesium sulfate vs standard care (ipratropium bromide) | no estimate extracted | NR | No studies |
Change in dyspnoea score Magnesium sulfate vs standard care (ipratropium bromide) | no estimate extracted | NR | No studies |
Lung function: FEV1 at 60 min Magnesium sulfate vs standard care (ipratropium bromide) | no estimate extracted | NR | No studies |